ストックスクリーナーアプリを入手
3.78
3.32%
-0.13
アフターアワーズ：
3.88
0.10
+2.65%
前日終値:
$3.91
開ける：
$3.89
24時間の取引高:
1.92M
Relative Volume:
0.59
時価総額：
$1.13B
収益：
-
当期純損益:
$-241.99M
株価収益率:
-4.026
EPS:
-0.9389
ネットキャッシュフロー:
$-133.64M
1週間 パフォーマンス:
+2.72%
1か月 パフォーマンス:
+18.87%
6か月 パフォーマンス:
-10.64%
1年 パフォーマンス:
+5.59%
1日の値動き範囲:
$3.71
$3.89
1週間の範囲:
$3.5602
$4.12
52週間の値動き範囲:
$2.61
$6.55
Sana Biotechnology Inc Stock (SANA) Company Profile
名前
Sana Biotechnology Inc
セクター
電話
(206) 701-7914
住所
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.78 | 1.12B | 0 | -241.99M | -133.64M | -0.9389 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-24 | 開始されました | Wedbush | Outperform |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-03-18 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | 開始されました | Jefferies | Buy |
| 2025-01-08 | アップグレード | TD Cowen | Hold → Buy |
| 2024-11-05 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | 開始されました | Rodman & Renshaw | Buy |
| 2024-01-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-09-05 | 開始されました | Citigroup | Buy |
| 2023-08-14 | 開始されました | TD Cowen | Market Perform |
| 2023-05-02 | 開始されました | H.C. Wainwright | Neutral |
| 2021-03-01 | 開始されました | BofA Securities | Buy |
| 2021-03-01 | 開始されました | Goldman | Neutral |
| 2021-03-01 | 開始されました | JP Morgan | Neutral |
| 2021-03-01 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Sana Biotechnology Inc (SANA) 最新ニュース
Sana Biotechnology (NASDAQ:SANA) Cell Therapy Vision Gains Attention - Kalkine Media
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative? - Sahm
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.2%Time to Sell? - MarketBeat
Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely? - Moomoo
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 8.9%Still a Buy? - MarketBeat
Can Sana Biotechnology (SANA) Justify Its Valuation On Narrower Losses? - Sahm
Alphabet Inc. Makes New $9.82 Million Investment in Sana Biotechnology, Inc. $SANA - MarketBeat
Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Sana Biotechnology (NASDAQ:SANA): Can Cell Therapy Drive the Next Chapter? - Kalkine Media
ARCH venture funds disclose 15%+ Sana Biotechnology (SANA) ownership in updated filing - Stock Titan
Sana Biotechnology | SCHEDULE 13G/A: Others - Moomoo
Bank of America Issues Pessimistic Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3%Should You Sell? - MarketBeat
Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.38, Implies 155% Upside - TradingView
BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7 - marketscreener.com
BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings - MarketBeat
Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity DealWhat's Changed - webull.com
Sana Biotechnology: Insulin-Producing Cells Survive 14 Months Without Immunosuppression As Mayo Clinic Invests $25 Million - Pulse 2.0
Wedbush Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
SANA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Sana Biotechnology | 10-Q: Quarterly report - moomoo.com
Sana Biotechnology non-GAAP EPS beats estimate; cash runway extends to mid-2027 - scanx.trade
Sana Biotechnology falls 5% despite beating earnings estimates By Investing.com - Investing.com India
Sana Biotechnology falls 5% despite beating earnings estimates - Investing.com
Sana Biotechnology Q2 adjusted loss narrows, beats estimates - Bitget
Sana Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results - MarketBeat
Sana Biotechnology Q2 Adjusted Loss Narrows - marketscreener.com
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q2 Adjusted Loss $0.13 per Share, vs. FactSet Est of $-0.12 - marketscreener.com
Sana Biotechnology (SANA) warns on going concern amid $110.8M loss - stocktitan.net
Sana: Q2 Earnings Snapshot - KTVB
BRIEF-Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15 - TradingView
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates - Yahoo Finance
Sana Biotechnology (SANA) Advances 2.56% as Shares Approach Key Resistance at $3.79Dip Buy Trade - vinanet.vn
Sana Biotechnology faces earnings test as CAR-T program advances By Investing.com - Investing.com UK
Sana Biotechnology faces earnings test as CAR-T program advances - Investing.com
Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Sana Biotechnology, Inc. (SANA) Stock Analysis: Exploring a Promising 151% Potential Upside - DirectorsTalk Interviews
Sana Biotechnology (SANA) Projected to Release Earnings on Monday - MarketBeat
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Sana Biotechnology Inc (SANA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sana Biotechnology Inc (SANA) Valuation: PE, PB & Fair Value Analysis - TradingKey
SANA|Sana Biotechnology Inc|Price:3.285|Chg%:+0.105 - TradingKey
Sana Biotechnology Inc (SANA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sana Biotechnology Inc (SANA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 6.8%Should You Buy? - MarketBeat
TradingKey - TradingKey
Sana Biotechnology Inc (SANA) Institutional Confidence - TradingKey
Sana Biotechnology: Promising Science, But Dilution Keeps The Rating A Hold (NASDAQ:SANA) - Seeking Alpha
Sana Biotechnology Inc (SANA) 財務データ
収益
当期純利益
現金流量
EPS
Sana Biotechnology Inc (SANA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Harr Steve | President & CEO |
Mar 06 '26 |
Option Exercise |
0.00 |
41,666 |
0 |
7,918,596 |
| Wyrick Susan D. | See Remarks |
Mar 07 '26 |
Option Exercise |
0.00 |
3,250 |
0 |
200,583 |
| Wyrick Susan D. | See Remarks |
Mar 06 '26 |
Option Exercise |
0.00 |
10,416 |
0 |
197,333 |
| Wyrick Susan D. | See Remarks |
Mar 02 '26 |
Option Exercise |
0.00 |
1,525 |
0 |
187,408 |
| Wyrick Susan D. | See Remarks |
Jan 02 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
188,290 |
| Wyrick Susan D. | See Remarks |
Dec 13 '25 |
Option Exercise |
0.00 |
3,400 |
0 |
181,663 |
| Wyrick Susan D. | See Remarks |
Dec 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
180,828 |
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):